Pfizer (PFE) Total Liabilities (2009 - 2026)

Pfizer (PFE) has reported Total Liabilities for 18 consecutive years, with $115.6 billion the latest figure, recorded in Q2 2026.

• On a quarterly basis, Total Liabilities fell 1.23% year-over-year to $115.6 billion in Q2 2026; TTM through Jun 2026 was $115.6 billion, a 1.23% decrease from a year earlier, with the FY2025 full-year figure at $121.4 billion, down 2.81% from the prior year.
• Total Liabilities was $115.6 billion for Q2 2026 at Pfizer, down from $117.2 billion in the prior quarter.
• Over five years, Total Liabilities peaked at $137.2 billion in Q4 2023 and troughed at $21.9 billion in Q3 2023.
• A 5-year average of $106.7 billion and a median of $117.1 billion in 2025 frame the typical range for Total Liabilities.
• Across the five-year window, Total Liabilities plunged 78.25% in 2022 and soared 480.54% in 2024, its largest moves.
• Over 5 years, Total Liabilities stood at $101.3 billion in 2022, then jumped by 35.47% to $137.2 billion in 2023, then decreased by 8.97% to $124.9 billion in 2024, then dropped by 2.81% to $121.4 billion in 2025, then declined by 4.73% to $115.6 billion in 2026.
• The last three Total Liabilities figures came in at $115.6 billion (Q2 2026), $117.2 billion (Q1 2026), and $121.4 billion (Q4 2025), per Business Quant data.